Erasca, Inc.
Clinical trials sponsored by Erasca, Inc., explained in plain language.
A clinical-stage biotech company developing precision oncology therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis study tests two experimental drugs, ERAS-007 and ERAS-601, in people with advanced solid tumors that have not responded to standard treatments. The drugs are taken orally and aim to block signals that help cancer grow. The trial will first find safe doses and then check if t…
Phase: PHASE1, PHASE2 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called ERAS-601, alone or with other cancer treatments, in adults with advanced solid tumors that have not responded to standard therapies. The main goals are to find safe doses and check for side effects. About 90 participants will take pa…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo targets tough cancers with RAS mutation
Disease control OngoingThis early-stage trial is testing whether a combination of two drugs, naporafenib and trametinib, can shrink or control advanced solid tumors that have a specific genetic change called RAS Q61X. About 86 people whose cancer has not responded to standard treatments will receive th…
Phase: PHASE1 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise for Tough-to-Treat skin cancer
Disease control OngoingThis study tests a new two-drug combination (naporafenib + trametinib) in people with advanced NRAS-mutant melanoma that has already been treated. The goal is to see if the combo works better than standard treatments at slowing cancer growth and extending life. About 78 adults wi…
Phase: PHASE3 • Sponsor: Erasca, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC